University of Groningen

The aberrant transcriptional program of myeloid malignancies with poor prognosis

Gerritsen, Mylène

DOI:
[10.33612/diss.113503008](https://doi.org/10.33612/diss.113503008)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Gerritsen, M. (2020). *The aberrant transcriptional program of myeloid malignancies with poor prognosis: the effects of RUNX1 and TP53 mutations in AML*. Rijksuniversiteit Groningen.
<https://doi.org/10.33612/diss.113503008>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

The aberrant transcriptional program of myeloid malignancies with poor prognosis

The effects of RUNX1 and TP53 mutations in AML

MYLÉNE GERRITSEN

COLOPHON

Cover design:	James Jardine www.jamesjardine.nl
Layout:	James Jardine www.jamesjardine.nl
Print:	Ridderprint www.ridderprint.nl
ISBN:	978-94-6375-764-5 (print) 978-94-6375-765-2 (digital)

Copyright © 2019 by Myléne Gerritsen. All rights reserved. Any unauthorized reprint or use of this material is prohibited. No part of this thesis may be reproduced, stored or transmitted in any form or by any means, without written permission of the author or, when appropriate, of the publishers of the publications.

rijksuniversiteit
 groningen

The aberrant transcriptional program of myeloid malignancies with poor prognosis

The effects of RUNX1 and TP53 mutations in AML

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 4 maart 2020 om 16.15 uur

door

Mylène Gerritsen

geboren op 16 oktober 1988
te Zevenaar

Promotores

Prof. dr. E. Vellenga

Prof. dr. J.J. Schuringa

Co-Promotor

Dr. J.H.A Martens

Beoordelingscommissie

Prof. dr. H.G. Stunnenberg

Prof. dr. G. de Haan

Prof. dr. M.A.T.M. van Vugt

TABLE OF CONTENTS

Chapter 1	General introduction and scope of the thesis	7
Chapter 2	<i>RUNX1</i> mutations enhance self-renewal and block granulocytic differentiation in human <i>in vitro</i> models and primary AMLs. <i>Blood Advances 2019; 3: 320</i>	27
Chapter 3	<i>TCF4</i> is an important target for mutant RUNX1 and its expression predicts clinical outcome in acute myeloid leukemia Parts are published in <i>Haematologica</i>	63
Chapter 4	Mutant p53 increases stem-cell frequency and has reduced binding to classic p53 binding sites in primary AMLs and cell lines. <i>Submitted</i>	85
Chapter 5	Ring sideroblasts in AML are clonally derived, associated with adverse risk characteristics and have a distinct gene expression pattern <i>Blood Advances 2019; 3: 3111</i>	103
Chapter 6	Summary, General Conclusion and Discussion	155
Appendices	Nederlandse samenvatting voor “niet ingewijden”	175
	Dankwoord	179
	List of Publications	183